Think of P4O as P4P with its eyes on the prize. Unfortunately, even ordinary P4P is not yet widespread.
Is the breast cancer drug Avastin the opening salvo that brings efficacy, toxicity, and costs together? Who will blink first — health plans, providers, regulators, or patients?
As the medical home concept grows, many in health care will have to define new roles
Health insurance plans need only bolster the following accepted guidelines to see a return on a very little bit of investment
With the advent of new disease-specific agents, some patients with HAE may find relief from its enormous physical and psychological toll
Michael Toscani, PharmD
Marc Riedl, MD, MS
Legislation & Regulation
In the long run, health plans will benefit from the new rules. In the short run, hospitals say they already have enough economic pressures.
Expect more denials as more specialty drugs are introduced and prescribed
The Formulary Files
For this condition that is largely confined to the Medicare population, a new treatment is now available
Thomas Morrow, MD
Managed Care Outlook